Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for GATTEX, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO). This determination is required by law and is published as a notice.